文献类型：期刊文献

中文题名：心外膜脂肪组织在射血分数保留型心衰合并2型糖尿病中的研究进展

英文题名：Research progress of epicardial adipose tissue in ejection fraction preserved heart failure with type 2 diabetes

作者：柏婷燕[1];易希善[1];刘凯[1];赵信科[2];吴雪[1];吕欣芳[1];蒋虎刚[1];李应东[1,2]

第一作者：柏婷燕

机构：[1]甘肃中医药大学,甘肃兰州730000;[2]甘肃中医药大学附属医院心血管科,甘肃兰州730000

第一机构：甘肃中医药大学

年份：2024

卷号：36

期号：6

起止页码：712

中文期刊名：心脏杂志

外文期刊名：Chinese Heart Journal

收录：CSTPCD

基金：甘肃省中医药防治重大疾病科研课题(GZKZD-2018-2)。

语种：中文

中文关键词：射血分数保留型心衰;2型糖尿病;心外膜脂肪组织;作用机制;治疗;研究进展

外文关键词：ejection fraction preserved heart failure;type 2 diabetes mellitus;epicardial adipose tissue;mechanism of action;treatment;research progress

摘要：射血分数保留型心力衰竭的患病率逐年升高,尽管目前不断改进的治疗方案在一定程度上降低了患者的死亡率,但其预后仍然较差,而针对其合并症进行治疗的方案更能改善患者的预后。2型糖尿病是其最常见的合并症,二者相互作用,推进了疾病的发生发展。故射血分数保留型心力衰竭合并2型糖尿病是一种严重的病理生理疾病,危害着人类健康,而其发病机制也十分复杂。近来有研究表明心外膜脂肪组织在射血分数保留型心衰合并2型糖尿病的发生发展中起着重要的作用。本文就心外膜脂肪组织在射血分数保留型心衰合并2型糖尿病中的可能的作用机制以及近年来的治疗研究进展作出阐述,以期为临床治疗射血分数保留型心衰合并2型糖尿病提供参考意见并拓展思路。
The prevalence of heart failure with preserved ejection fraction is increasing year by year,and although current continuously improved treatment regimens reduce the mortality of patients to some extent,their prognosis is still poor,whereas regimens that target their comorbidities improve the prognosis of patients more.Type 2 diabetes is its most common comorbidity,and the two interact to advance the disease process.Therefore,heart failure with preserved ejection fraction(HFpEF)combined with type 2 diabetes mellitus(T2DM)is a serious pathophysiological disease that endangers human health,while its pathogenesis is also very complex.Recently,it has been shown that epicardial adipose tissue plays an important role in the development of heart failure with preserved ejection fraction and type 2 diabetes.This review focuses on the possible role of epicardial adipose tissue in the management of heart failure with preserved ejection fraction and type 2 diabetes and the recent advances in therapeutic research in the future,with a view to providing insights and expanding the therapeutic repertoire for the clinical treatment of heart failure with preserved ejection fraction and type 2 diabetes.